Compugen, AstraZeneca reach 1st milestone in deal

By The Science Advisory Board staff writers

December 23, 2020 -- Compugen announced it is entitled to receive $2 million upon reaching the first preclinical milestone in an ongoing license agreement with AstraZeneca for the development of antibody products.

Under the deal, AstraZeneca received an exclusive license for the development of bispecific and multispecific antibody products based on one of Compugen's pipeline programs.

Compugen received a $10 million upfront payment and is eligible to receive up to $200 million in development, regulatory, and commercial milestones for the first product, as well as tiered royalties on future product sales, the company said.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.